While there was an abundance of data presented last week at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, most of it was incremental in terms of the impact on clinical practice, analysts said. (BioWorld Financial Watch)

While data from the much-anticipated FLEX Phase III study showed that ImClone Systems Inc.'s Erbitux (cetuximab) prolonged life by about five weeks for patients with non-small-cell lung cancer (NSCLC), findings from another study of the drug in colorectal cancer showed that patients with the KRAS gene mutation were unlikely to benefit from Erbitux. (BioWorld Today)

Syndexa Pharmaceuticals Corp.'s bank account got a $15 million boost in a Series B financing round, which will allow the firm to advance its metabolic disease product platform. (BioWorld Today)